Rani Therapeutics (RANI) Stock Price, News & Analysis

Company Overview

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery. In addition to its insulin candidate, the company is exploring oral formulations of GLP-1 receptor agonists and other therapeutic proteins. Rani has secured investigational new drug (IND) approvals and completed initial safety and pharmacokinetic assessments in humans, positioning its RaniPill platform for broader application across multiple chronic disease areas.

Headquartered in San Jose, California, Rani Therapeutics leverages collaborations with research institutions and industry partners to streamline development and manufacturing. While still in the clinical stages, the company is preparing for pivotal trials and regulatory interactions to support future commercialization. Rani’s management team combines expertise from pharmaceutical development, medical device engineering and regulatory affairs, underscoring its commitment to transforming biologic drug delivery and expanding patient access globally.

Key Stats

• Today's Range: $0.45 to $0.48
• 50-Day Range: $0.46 to $0.62
• 52-Week Range: $0.39 to $3.75
• Volume: 576,532 shs
• Average Volume: 303,949 shs
• Market Capitalization: $33.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.33
• Consensus Rating: Moderate Buy

Rani Therapeutics Stock Analysis - MarketRank™

Rani Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 332nd out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rani Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Rani Therapeutics has a consensus price target of $7.33, representing about 1,465.3% upside from its current price of $0.47.

Amount of Analyst Coverage

Rani Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rani Therapeutics are expected to grow in the coming year, from ($1.01) to ($0.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rani Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rani Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rani Therapeutics has a P/B Ratio of 7.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.18% of the float of Rani Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rani Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rani Therapeutics has recently decreased by 38.16%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rani Therapeutics does not currently pay a dividend.

Dividend Growth

Rani Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.18% of the float of Rani Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rani Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rani Therapeutics has recently decreased by 38.16%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 0.95

News Sentiment

Rani Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Rani Therapeutics this week, compared to 1 article on an average week.

Search Interest

11 people have searched for RANI on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.

MarketBeat Follows

1 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rani Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

45.08% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.19% of the stock of Rani Therapeutics is held by institutions.

RANI Stock Analysis - Frequently Asked Questions

How have RANI shares performed this year?

Rani Therapeutics' stock was trading at $1.37 on January 1st, 2025. Since then, RANI shares have decreased by 65.8% and is now trading at $0.4685.

How were Rani Therapeutics' earnings last quarter?

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) released its quarterly earnings data on Thursday, August, 7th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01.

When did Rani Therapeutics IPO?

Rani Therapeutics (RANI) raised $100 million in an initial public offering on Friday, July 30th 2021. The company issued 6,666,667 shares at $14.00-$16.00 per share.

How do I buy shares of Rani Therapeutics?

Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rani Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rani Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Honeywell International (HON), CrowdStrike (CRWD), Cisco Systems (CSCO), Intel (INTC) and CocaCola (KO).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/13/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RANI
• CIK: 1856725
• Web: www.ranitherapeutics.com
• Phone: 408-457-3700
• Fax: N/A
• Employees: 110
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Rani Therapeutics: $7.33
• High Price Target: $9.00
• Low Price Target: $4.00
• Potential Upside/Downside: +1,465.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.02 million
• Net Margins: N/A
• Pretax Margin: -4,367.17%
• Return on Equity: -1,258.76%
• Return on Assets: -97.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.54
• Quick Ratio: 0.54

Sales & Book Value

• Annual Sales: $1.03 million
• Price / Sales: 32.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.06 per share
• Price / Book: 7.81

Miscellaneous

• Outstanding Shares: 71,870,000
• Free Float: 39,470,000
• Market Cap: $33.67 million
• Optionable: Optionable
• Beta: -0.02